Rhumbline Advisers Point Biopharma Global Inc. Transaction History

Rhumbline Advisers

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$6.67 - $9.71 $14,013 - $20,400	2,101 Added 1.45%	147,167 $981,000
Q2 2023 Aug 08, 2023	BUY	$6.86 - $10.86 $217,750 - $344,718	31,742 Added 28.01%	145,066 $1.31 Million
Q1 2023 May 11, 2023	BUY	$6.78 - $8.1 $83,692 - $99,986	12,344 Added 12.22%	113,324 $824,000
Q4 2022 Feb 14, 2023	BUY	$5.72 - $9.78 $46,457 - $79,433	8,122 Added 8.75%	100,980 $736,000
Q3 2022 Nov 10, 2022	BUY	$7.24 - $10.31 $47,639 - $67,839	6,580 Added 7.63%	92,858 $718,000
Q2 2022 Aug 11, 2022	BUY	$5.6 - $9.5 $483,156 - $819,641	86,278 New	86,278 $588,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.